Increased seizure threshold and severity in young transgenic CRND8 mice

Neuroscience Letters

Volumn 367, Issue 2, 2004, Pages 164-167

  Del Vecchio, Robert A ^a   Gold, Lisa H ^b   Novick, Steve J ^c   Wong, Gwen ^d   Hyde, Lynn A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PFIZER INC   (United States)

^c GLAXOSMITHKLINE   (United States)

^d ALS Therapy Development Institute   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; CRND8 mouse; Seizure threshold; Seizures

Indexed keywords

AMYLOID BETA PROTEIN; PENTETRAZOLE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL MODEL; FEMALE; GENOTYPE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE THRESHOLD; SENILE PLAQUE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PENTYLENETETRAZOLE; SEIZURES; SENSORY THRESHOLDS; STATISTICS, NONPARAMETRIC;

EID: 4344564473     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2004.05.107     Document Type: Article

References (23)

1. Armon C., Peterson G.W., Liwnicz B.H. Alzheimer's disease underlies some cases of complex partial status epilepticus. J. Clin. Neurophysiol. 17(4):2000;511-518
2. Chishti M.A., Yang D.-S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., St. George-Hyslop P., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276(24):2001;21562-21570
3. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Lieberburg I., Selkoe D.J. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature. 360:1992;672-674
4. Ferraro T.N., Golden G.T., Smith G.G., St. Jean P., Schork N.J., Mulholland N., Ballas C., Schill J., Buono R.J., Berrettini W.H. Mapping loci for Pentylenetetrazol-induced seizure susceptibility in mice. J. Neurosci. 19(16):1999;6733-6739
5. Hauser W.A., Morris M.L., Heston L.L., Elving Anderson V. Seizures and myoclonus in patients with Alzheimer's disease. Neurology. 36:1986;1226-1230
6. Hint H.C., Richter A.W. A simple intravenous infusion technique for mice: method and some applications. Acta Pharmacol. Toxicol. 14:1958;153-157
7. A) receptors: mechanism and site of action. J. Pharm. Exp. Ther. 298(3):2001;286-295
8. swe/ind CRND8 mice. Neurobiol. Dis. 11:2002;394-409
9. Kamenetz J., Tomita T., Hsieh H., Seabrook G., Brochelt D., Iwatsubo T., Sisodea S., Malinow R. APP processing and synaptic function. Neuron. 37:2003;925-937
10. Kosobud A.E., Crabbe J.C. Genetic correlations among inbred strain sensitivities to convulsions induced by 9 convulsant drugs. Brain Res. 526(1):1990;8-16
11. Mendez M.F., Catanzaro P., Doss R.C., Arguello R., Frey W.H. Seizures in Alzheimer's disease: clinicopathologic study. J. Geriatr. Psychiatry Neurol. 7(4):1994;230-233
12. Mohajeri M.H., Saini K., Schultz J.G., Wollmer M.A., Hock C., Nitsch R.M. Passive immunization against β-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J. Biol. Chem. 277(36):2002;33012-33017
13. 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20(11):2000;4050-4058
14. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroenceph. Clin. Neurophysiol. 32:1972;281-294
15. Risse S.C., Lampe T.H., Bird T.D., Nichlin D., Sumi S.M., Kennan T., Cubberley L., Peskind E., Raskind M.A. Myoclonus, seizures and paratonia in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 4(4):1990;217-225
16. Roher A.E., Lowenson J.D., Clarke S., Woods A.S., Cotter R.J., Gowing E., Ball M.J. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90:1993;10836-10840
17. Romanelli M.F., Morris J.C., Ashkin K., Coben L.A. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch. Neurol. 47:1990;847-850
18. Schneider I., Reverse D., Dewachter I., Ris L., Caluwaerts N., Kuiperi C., Gilis M., Geerts H., Kretzschmar H., Godaux E., Moechars D., Van Leuven F., Herms J. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold of excitotoxicity and facilitating long-term potentiation. J. Biol. Chem. 276(15):2001;11539-11544
19. Shneker B.F., Fountain N.B. Epilepsy Dis. Mon. 49:2003;426-478
20. Sjobeck M., Englund E. Glial levels determine severity of white matter disease in Alzheimer's disease: a neuropathological study of glial changes. Neuropathol. Appl. Neurobiol. 29:2003;159-169
21. Sodeyama N., Iwata T., Ishikawa K., Mizusawa H., Yamada M., Itoh Y., Otomo E., Matsushita M., Komatsuzaki Y. Very early onset Alzheimer's disease with spastic paraparesis associated with a novel presenilin 1 mutation (Phe237Ile). J. Neurol. Neurosurg. Psychiatry. 71:2001;556-557
22. Spann P.E.J., Raaijmakers J.G.W., Jonker C. Alzheimer's disease versus normal ageing: a review of the efficiency of clinical and experimental memory measures. J. Clin. Exp. Neuropsychol. 25(2):2003;216-233
23. 717) mutants. Science. 264:1994;1336-1340